Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.

IF 4 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2025-09-29 DOI:10.1080/14712598.2025.2567868

Mahmoud Ines, Zarrouk Zeineb, Bouden Selma, Saidane Olfa, Rouached Leila, Tekaya Rawdha, Ben Tekaya Aicha, Dziri Chadli, Abdelmoula Leila

{"title":"Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.","authors":"Mahmoud Ines, Zarrouk Zeineb, Bouden Selma, Saidane Olfa, Rouached Leila, Tekaya Rawdha, Ben Tekaya Aicha, Dziri Chadli, Abdelmoula Leila","doi":"10.1080/14712598.2025.2567868","DOIUrl":null,"url":null,"abstract":"Objectives: To assess the effectiveness and safety of Rituximab (RTX) treatment among patients diagnosed with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).Methods: We performed a systematic review with meta-analysis of studies involving patients with RA-ILD who were treated with RTX. Two investigators independently conducted the research.Results: Twenty studies met the criteria for data extraction for the systematic review with a good quality assessment according to an 18-criteria checklist using a modified Delphi method. The total number of patients was 14,523, including 1,619 who received RTX. Stabilization or improvement was observed in more than half of the patients in all studies. Evaluation based on pulmonary function tests (PFTs) noted disease progression in fewer than 20% of 7 out of 11 studies. Meta-analysis results revealed that, based on PFTs, the proportion of patients showing functional decline was 14.5% (95%CI, 7.6-25.8%) (95%PI, 2-69%); and according to the pulmonary high-resolution computed tomography (HRCT) evaluation, the proportion of worsening was 19.5% (95%CI, 8.1-40%) (95%PI, 1-84%). An overall acceptable safety profile was noted, with respiratory mortality ranging from 4% to 14%.Conclusion: Our review suggests that RTX appears to be an effective therapy in patients with RA-ILD, with a satisfactory safety profile.Protocol registration: https://www.crd.york.ac.uk/prospero identifier is CRD420251049957.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2025.2567868","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To assess the effectiveness and safety of Rituximab (RTX) treatment among patients diagnosed with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Methods: We performed a systematic review with meta-analysis of studies involving patients with RA-ILD who were treated with RTX. Two investigators independently conducted the research.

Results: Twenty studies met the criteria for data extraction for the systematic review with a good quality assessment according to an 18-criteria checklist using a modified Delphi method. The total number of patients was 14,523, including 1,619 who received RTX. Stabilization or improvement was observed in more than half of the patients in all studies. Evaluation based on pulmonary function tests (PFTs) noted disease progression in fewer than 20% of 7 out of 11 studies. Meta-analysis results revealed that, based on PFTs, the proportion of patients showing functional decline was 14.5% (95%CI, 7.6-25.8%) (95%PI, 2-69%); and according to the pulmonary high-resolution computed tomography (HRCT) evaluation, the proportion of worsening was 19.5% (95%CI, 8.1-40%) (95%PI, 1-84%). An overall acceptable safety profile was noted, with respiratory mortality ranging from 4% to 14%.

Conclusion: Our review suggests that RTX appears to be an effective therapy in patients with RA-ILD, with a satisfactory safety profile.

Protocol registration: https://www.crd.york.ac.uk/prospero identifier is CRD420251049957.

查看原文本刊更多论文

利妥昔单抗治疗类风湿关节炎相关间质性肺疾病的疗效和安全性：一项系统综述和荟萃分析

目的：评估利妥昔单抗（RTX）治疗类风湿性关节炎相关间质性肺疾病（RA-ILD）患者的有效性和安全性。方法：我们对接受RTX治疗的RA-ILD患者的研究进行了系统回顾和荟萃分析。两名调查人员独立进行了这项研究。结果：20项研究符合系统评价的数据提取标准，使用改进的德尔菲法根据18项标准检查表进行了良好的质量评估。患者总数为14,523人，其中接受RTX治疗的患者为1,619人。在所有研究中，超过一半的患者观察到稳定或改善。基于肺功能测试（PFTs）的评估显示，在11项研究中，7项研究中疾病进展率不到20%。meta分析结果显示，基于pft，出现功能下降的患者比例为14.5% (95%CI, 7.6-25.8%) (95%PI, 2-69%)；肺部高分辨率计算机断层扫描（HRCT）评估，恶化比例为19.5% (95%CI, 8.1-40%) （95%PI, 1-84%）。注意到总体可接受的安全性概况，呼吸系统死亡率在4%至14%之间。结论：我们的综述表明RTX似乎是RA-ILD患者的有效治疗方法，具有令人满意的安全性。协议注册：https://www.crd.york.ac.uk/prospero标识为CRD420251049957。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.